The estimated Net Worth of William Fairey is at least $5.92 millió dollars as of 1 February 2020. Mr. Fairey owns over 8,125 units of MyoKardia stock worth over $1,827,394 and over the last 7 years he sold MYOK stock worth over $0. In addition, he makes $4,090,180 as Executive Vice President and Chief Commercial Officer at MyoKardia.
Sign up
Mr. Fairey MYOK stock SEC Form 4 insiders trading
William has made over 1 trades of the MyoKardia stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,125 units of MYOK stock worth $1,827,394 on 1 February 2020.
The largest trade he's ever made was exercising 8,125 units of MyoKardia stock on 1 February 2020 worth over $1,827,394. On average, William trades about 677 units every 0 days since 2018. As of 1 February 2020 he still owns at least 8,125 units of MyoKardia stock.
You can see the complete history of Mr. Fairey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Fairey biography
William C. Fairey is Executive Vice President and Chief Commercial Officer of the Company. Prior to joining us and from March 2018 to January 2019, he served as executive vice president and chief commercial officer of ChemoCentryx, Inc., a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. During that time, he was responsible for the sales, marketing, medical affairs and market access functions, including commercialization of late stages compounds. Prior to ChemoCentryx, Mr. Fairey served in various roles at Actelion Pharmaceuticals Ltd. and its subsidiaries including president of Actelion Pharmaceuticals US, Inc., a pharmaceuticals and biotechnology company that specializes in orphan diseases, from April 2013 to December 2017, regional vice president, Australia Asia Pacific, of Actelion Pharmaceuticals Ltd. from July 2008 to March 2013, president of Actelion Pharmaceuticals Canada Inc. from June 2003 to June 2008, and vice president of sales and managed markets of Actelion Pharmaceuticals US, Inc. from January 2001 to June 2003. Mr. Fairey holds a B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary’s College of California.
What is the salary of William Fairey?
As the Executive Vice President and Chief Commercial Officer of MyoKardia, the total compensation of William Fairey at MyoKardia is $4,090,180. There are 1 executives at MyoKardia getting paid more, with Tassos Gianakakos having the highest compensation of $10,223,600.
How old is William Fairey?
William Fairey is 55, he's been the Executive Vice President and Chief Commercial Officer of MyoKardia since 2019. There are 6 older and 5 younger executives at MyoKardia. The oldest executive at MyoKardia, Inc. is Mary Cranston, 72, who is the Independent Director.
What's William Fairey's mailing address?
William's mailing address filed with the SEC is C/O AILERON THERAPEUTICS, INC., 12407 N. MOPAC EXPY. SUITE 250 #390, AUSTIN, TX, 78758.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr és Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Mr. Fairey stock trades at ChemoCentryx Inc, KalVista Pharmaceuticals Inc, MyoKardia, Aileron Therapeutics Inc és Mirum Pharmaceuticals Inc
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,